Literature DB >> 24516025

Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy.

Siraj M Ali1, R Katherine Alpaugh2, Sean R Downing1, Philip J Stephens1, Jian Q Yu2, Hong Wu2, Jamie K Buell1, Vincent A Miller1, Doron Lipson1, Gary A Palmer1, Jeffrey S Ross3, Massimo Cristofanilli4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24516025      PMCID： PMC4876358          DOI： 10.1200/JCO.2013.49.0599

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

Authors:  Heidi Greulich; Bethany Kaplan; Philipp Mertins; Tzu-Hsiu Chen; Kumiko E Tanaka; Cai-Hong Yun; Xiaohong Zhang; Se-Hoon Lee; Jeonghee Cho; Lauren Ambrogio; Rachel Liao; Marcin Imielinski; Shantanu Banerji; Alice H Berger; Michael S Lawrence; Jinghui Zhang; Nam H Pho; Sarah R Walker; Wendy Winckler; Gad Getz; David Frank; William C Hahn; Michael J Eck; D R Mani; Jacob D Jaffe; Steven A Carr; Kwok-Kin Wong; Matthew Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

2.  A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.

Authors:  Meghan L Rudd; Jessica C Price; Sarah Fogoros; Andrew K Godwin; Dennis C Sgroi; Maria J Merino; Daphne W Bell
Journal:  Clin Cancer Res       Date:  2011-01-25       Impact factor: 12.531

3.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

Authors:  S Dawood; S D Merajver; P Viens; P B Vermeulen; S M Swain; T A Buchholz; L Y Dirix; P H Levine; A Lucci; S Krishnamurthy; F M Robertson; W A Woodward; W T Yang; N T Ueno; M Cristofanilli
Journal:  Ann Oncol       Date:  2010-07-05       Impact factor: 32.976

Review 4.  Inflammatory breast cancer: the disease, the biology, the treatment.

Authors:  Fredika M Robertson; Melissa Bondy; Wei Yang; Hideko Yamauchi; Shannon Wiggins; Samira Kamrudin; Savitri Krishnamurthy; Huong Le-Petross; Luc Bidaut; Audrey N Player; Sanford H Barsky; Wendy A Woodward; Thomas Buchholz; Anthony Lucci; Naoto T Ueno; Naoto Ueno; Massimo Cristofanilli
Journal:  CA Cancer J Clin       Date:  2010-10-19       Impact factor: 508.702

5.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

6.  Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Authors:  Ron Bose; Shyam M Kavuri; Adam C Searleman; Wei Shen; Dong Shen; Daniel C Koboldt; John Monsey; Nicholas Goel; Adam B Aronson; Shunqiang Li; Cynthia X Ma; Li Ding; Elaine R Mardis; Matthew J Ellis
Journal:  Cancer Discov       Date:  2012-12-07       Impact factor: 39.397

7.  Lung cancer: intragenic ERBB2 kinase mutations in tumours.

Authors:  Philip Stephens; Chris Hunter; Graham Bignell; Sarah Edkins; Helen Davies; Jon Teague; Claire Stevens; Sarah O'Meara; Raffaella Smith; Adrian Parker; Andy Barthorpe; Matthew Blow; Lisa Brackenbury; Adam Butler; Oliver Clarke; Jennifer Cole; Ed Dicks; Angus Dike; Anja Drozd; Ken Edwards; Simon Forbes; Rebecca Foster; Kristian Gray; Chris Greenman; Kelly Halliday; Katy Hills; Vivienne Kosmidou; Richard Lugg; Andy Menzies; Janet Perry; Robert Petty; Keiran Raine; Lewis Ratford; Rebecca Shepherd; Alexandra Small; Yvonne Stephens; Calli Tofts; Jennifer Varian; Sofie West; Sara Widaa; Andrew Yates; Francis Brasseur; Colin S Cooper; Adrienne M Flanagan; Margaret Knowles; Suet Y Leung; David N Louis; Leendert H J Looijenga; Bruce Malkowicz; Marco A Pierotti; Bin Teh; Georgia Chenevix-Trench; Barbara L Weber; Siu T Yuen; Grace Harris; Peter Goldstraw; Andrew G Nicholson; P Andrew Futreal; Richard Wooster; Michael R Stratton
Journal:  Nature       Date:  2004-09-30       Impact factor: 49.962

Review 8.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

Authors:  Jeffrey S Ross; Elzbieta A Slodkowska; W Fraser Symmans; Lajos Pusztai; Peter M Ravdin; Gabriel N Hortobagyi
Journal:  Oncologist       Date:  2009-04-03

Review 9.  Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils.

Authors:  Davide Torti; Livio Trusolino
Journal:  EMBO Mol Med       Date:  2011-09-23       Impact factor: 12.137
  9 in total
  20 in total

Review 1.  Novel molecular targets for urothelial carcinoma.

Authors:  Bishoy M Faltas; Beerinder S Karir; Scott T Tagawa; Jonathan E Rosenberg
Journal:  Expert Opin Ther Targets       Date:  2015-01-30       Impact factor: 6.902

2.  Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.

Authors:  Matthias Christgen; Stephan Bartels; Angelina Luft; Sascha Persing; Daniel Henkel; Ulrich Lehmann; Hans Kreipe
Journal:  Virchows Arch       Date:  2018-08-09       Impact factor: 4.064

3.  HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.

Authors:  Noa Efrat Ben-Baruch; Ron Bose; Shyam M Kavuri; Cynthia X Ma; Matthew J Ellis
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

4.  [Main results of studies on primary therapy of head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014].

Authors:  A Gliese; C-J Busch; R Knecht
Journal:  HNO       Date:  2014-11       Impact factor: 1.284

5.  Intrinsic HER2 V777L mutation mediates resistance to trastuzumab in a breast cancer patient.

Authors:  Yosuke Hirotsu; Hiroshi Nakagomi; Kenji Amemiya; Toshio Oyama; Masayuki Inoue; Hitoshi Mochizuki; Masao Omata
Journal:  Med Oncol       Date:  2016-11-29       Impact factor: 3.064

6.  Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Authors:  Siraj M Ali; Eric M Sanford; Samuel J Klempner; Douglas A Rubinson; Kai Wang; Norma A Palma; Juliann Chmielecki; Roman Yelensky; Gary A Palmer; Deborah Morosini; Doron Lipson; Daniel V Catenacci; Fadi Braiteh; Rachel Erlich; Philip J Stephens; Jeffrey S Ross; Sai-Hong Ignatius Ou; Vincent A Miller
Journal:  Oncologist       Date:  2015-04-16

Review 7.  Prevalence and role of HER2 mutations in cancer.

Authors:  Emiliano Cocco; Salvatore Lopez; Alessandro D Santin; Maurizio Scaltriti
Journal:  Pharmacol Ther       Date:  2019-04-02       Impact factor: 12.310

8.  Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.

Authors:  Juliann Chmielecki; Jeffrey S Ross; Kai Wang; Garrett M Frampton; Gary A Palmer; Siraj M Ali; Norma Palma; Deborah Morosini; Vincent A Miller; Roman Yelensky; Doron Lipson; Philip J Stephens
Journal:  Oncologist       Date:  2014-12-05

9.  Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib.

Authors:  Yuxia Jia; Siraj M Ali; Shumaila Saad; Courtney A Chan; Vincent A Miller; Balazs Halmos
Journal:  Cancer Biol Ther       Date:  2014-05-16       Impact factor: 4.742

Review 10.  Genomic alterations of ERBB receptors in cancer: clinical implications.

Authors:  Rosalin Mishra; Ariella B Hanker; Joan T Garrett
Journal:  Oncotarget       Date:  2017-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.